Πλοήγηση ανά Θέμα "everolimus"
Αποτελέσματα 1-9 από 9
-
Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(−) breast cancer receiving salvage treatment with everolimus/exemestane
(2021)Purpose: Detection of CTCs represents a poor prognostic factor in patients with early and metastatic breast cancer (mBC) and treatment with everolimus–exemestane (E/E) is an established effective treatment in hormone ... -
The effect of anti‑HLA class I antibodies on the immunological properties of human glomerular endothelial cells and their modification by mTOR inhibition or GCN2 kinase activation
(2021)In antibody‑mediated rejection (ABMR), the graft endothelium is at the forefront of the kidney transplant against the assault from the recipient's humoral immune system, and is a target of the latter. The present study ... -
Histopathological evaluation of a retinoic acid eluting stent in a rabbit iliac artery model
(2022)This study aimed to evaluate the safety and efficacy of innovative retinoic acid (RA) eluting stents with bioabsorbable polymer. Sixty stents divided in ten groups were implanted in the iliac arteries of 30 rabbits. Two ... -
In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity
(2017)Purpose: Acute cellular rejection is the major cause of immune-mediated graft failure early in the course of kidney transplantation, whereas chronic antibody-mediated rejection is a major contributor to graft loss in the ... -
Investigation of the drug release time from the biodegrading coating of an everolimus eluting stent
(2021)This case-study examines the release time of the everolimus drug from an experimental biodegrading coating of a Rontis corp. drug eluting stent (DES). The controlled drug release is achieved by the degradation of the ... -
Quiz: Nine Years of Persistent, Disabling Foot Pain in a Kidney Transplant Recipient
(2017)[No abstract available] -
Systemic sclerosis: From pathogenesis towards targeted immunotherapies
(2012)Systemic sclerosis (SSc), a chronic disease with widespread collagen deposition, has three pathogenetic facets: immune activation, microvasculopathy and fibroblast activation. Immune activation and microvasculopathy occur ... -
Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirement
(2018)Introduction: The immunosuppressive therapy with everolimus (ERL) after heart transplantation is characterized by a narrow therapeutic window and a substantial variability in dose requirement. Factors explaining this ...